129 related articles for article (PubMed ID: 26151759)
1. Clinical features and treatment outcome of very elderly patients over 80 years old with multiple myeloma: comparison with patients in different age groups in the era of novel agents.
Matsue K; Matsue Y; Fujisawa M; Fukumoto K; Suehara Y; Sugihara H; Takeuchi M
Leuk Lymphoma; 2016; 57(1):110-5. PubMed ID: 26151759
[TBL] [Abstract][Full Text] [Related]
2. Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.
Offidani M; Corvatta L; Polloni C; Centurioni R; Visani G; Brunori M; Gentili S; Catarini M; Samori A; Blasi N; Alesiani F; Caraffa P; Burattini M; Galieni P; Fraticelli P; Ferranti M; Giuliodori L; Leoni P
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):423-32. PubMed ID: 22981966
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.
Dimopoulos MA; Kastritis E; Delimpasi S; Katodritou E; Hatzimichael E; Kyrtsonis MC; Repousis P; Tsirogianni M; Kartasis Z; Parcharidou A; Michael M; Michalis E; Tsatalas C; Stefanoudaki E; Hatjiharissi E; Gika D; Symeonidis A; Terpos E; Zervas K;
Eur J Haematol; 2012 Jul; 89(1):10-5. PubMed ID: 22469521
[TBL] [Abstract][Full Text] [Related]
4. Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report.
An N; Li X; Shen M; Chen S; Huang Z
World J Surg Oncol; 2015 Aug; 13():239. PubMed ID: 26245342
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma.
Kim SM; Kim MJ; Jung HA; Kim K; Kim SJ; Jang JH; Kim WS; Jung CW
Biomed Res Int; 2014; 2014():437852. PubMed ID: 25114902
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Clinicopathological Parameters Affecting the Outcome in Egyptian Patients with Multiple Myeloma.
Sallam YA; Samra MA; Gaber AA
Gulf J Oncolog; 2016 Jan; 1(20):51-63. PubMed ID: 27050180
[TBL] [Abstract][Full Text] [Related]
7. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
Lakshman A; Abeykoon JP; Kumar SK; Rajkumar SV; Dingli D; Buadi FK; Gonsalves WI; Leung N; Dispenzieri A; Kourelis TV; Go RS; Lacy MQ; Hobbs MA; Lin Y; Warsame R; Lust J; Fonder AL; Hwa YL; Hayman SR; Russell SJ; Kyle RA; Gertz MA; Kapoor P
Am J Hematol; 2017 Nov; 92(11):1146-1155. PubMed ID: 28799231
[TBL] [Abstract][Full Text] [Related]
9. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
[TBL] [Abstract][Full Text] [Related]
11. Clinical course and prognosis of non-secretory multiple myeloma.
Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
[TBL] [Abstract][Full Text] [Related]
12. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
Ann Hematol; 2017 Mar; 96(3):441-448. PubMed ID: 27913860
[TBL] [Abstract][Full Text] [Related]
13. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes in Elderly Patients Treated for Oral Cavity Squamous Cell Carcinoma.
Chen JJ; Shah JL; Harris JP; Bui TT; Schaberg K; Kong CS; Kaplan MJ; Divi V; Schoppy D; Le QT; Hara WY
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):775-783. PubMed ID: 28602409
[TBL] [Abstract][Full Text] [Related]
15. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Kaneko H; Yagi H; Shibayama H; Tanaka H; Kosugi S; Uoshima N; Kobayashi M; Adachi Y; Ohta K; Ishii K; Uchiyama H; Matsuda M; Nakatani E; Tsudo M; Shimazaki C; Takaori-Kondo A; Nomura S; Matsumura I; Taniwaki M; Kanakura Y;
Int J Hematol; 2015 Jan; 101(1):37-45. PubMed ID: 25385278
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
17. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
Iriuchishima H; Saitoh T; Handa H; Isoda A; Matsumoto M; Sawamura M; Iwasaki A; Ushie C; Hattori H; Sasaki Y; Mitsui T; Yokohama A; Tsukamoto N; Murakami H; Nojima Y
Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
[TBL] [Abstract][Full Text] [Related]
18. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
[TBL] [Abstract][Full Text] [Related]
19. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
20. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
